[ad_1]
Pfizer has not completed its knowledge of producing its vaccine at a very rapid rate, as it is currently investigating the possibility of using it for younger age groups, unless it triggers a surprise on the epidemic which extinguished all hopes with him.
Company CEO Albert Burla confirmed on Tuesday that he expects to face “constant demand” for the emerging coronavirus vaccine, similar to influenza vaccines, reflecting the pharmaceutical giant’s expectations that the coronavirus will remain common and treated like the others. diseases.
In press releases following the announcement of the company’s quarterly business results, he expressed pride in how Pfizer began in 2021, noting that it continued to ramp up production and shipping of the vaccine. and, in many cases, exceeded its contractual obligations with respect to the delivery schedule.
He also pointed out that data presented to the U.S. Food and Drug Administration on Friday shows that the vaccine can be stored in the refrigerator for four weeks, making it easier for vaccination centers that do not have refrigerators to store the vaccine, according to the “Financial Times” newspaper.
The storage dilemma
At the same time, the company revealed that it is working on developing a new vaccine that can be refrigerated for up to 10 weeks, and data on that is due in August.
Pfizer vaccine
The company’s stock price rose after quarterly results were revealed 1% in pre-opening U.S. stock market trades today.
The company revealed that its profits rose in the first quarter to $ 14.6 billion, a 45% increase from the same period last year, and more than analysts’ expectations.
It is noteworthy that scientific efforts to achieve the development of a second generation of vaccines against the emerging virus continue, while “the enemy of humanity” is launching its attack on the whole world, because it has infected more than 154 million. people so far, and has resulted in the deaths of over two million people.
In the new developments, U.S. pharmaceutical companies and government labs are working to develop Corona vaccines that are taken as pills or nasal sprays, and they are easier to store than current vaccines that are taken by injection, according to the “Street Wall Journal.”
Longer immunity
These vaccines will also have the ability to provide immune responses that last longer and be more effective against mutated strains, according to the developed companies, which could help prevent epidemics in the future.
Pfizer logo
It should be noted that vaccines currently licensed in the United States, such as “Pfizer” and “Moderna”, require very low temperatures to store and transport them, and the person receiving the vaccine takes two doses at separate intervals. .
Source link
